Advice
In the absence of a submission from the holder of the marketing authorisation:
deferasirox (Exjade®) is not recommended for use within NHS Scotland.
Indication under review: treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice39KB (PDF)
Medicine details
- Medicine name:
- deferasirox (Exjade)
- SMC ID:
- 866/13
- Indication:
- Treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 April 2013